Kyowa Kirin Co. Ltd (KYKOF PINK) stock market data APIs
$14.4195
0(0%)
as of August 14, 2026
Try our APIs with
free plan!
Kyowa Kirin Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
Prev. Close
14.4195
Open
14.4195
High
14.4195
Low
14.4195
52 wk Range
12.42-18
Market Cap
7 553 M
P/E Ratio
14.5707
Shares Outstanding
524 M
Revenue
529 801 M
EPS
0.2227
Dividends (Yield)
0.0309
Beta
0.135
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kyowa Kirin Co. Ltd data using free add-ons & libraries
Get Kyowa Kirin Co. Ltd Fundamental Data
Kyowa Kirin Co. Ltd Fundamental data includes:
- Net Revenue: 529 801 M
- EBITDA: 158 421 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-03
- EPS/Forecast: 34.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kyowa Kirin Co. Ltd News
New
Should Stronger Half-Year Profitability at Kyowa Kirin (TSE:4151) Require Action From Investors?
Kyowa Kirin Co., Ltd. recently reported half-year 2026 results, with sales rising to ¥263,629 million and net income reaching ¥30,618 million, alongside basic earnings per share from continuing oper...
Kyowa Kirin Non-GAAP EPS of ¥103.26, revenue of ¥263.63B; reaffirms FY 2026 outlook
* Kyowa Kirin press release [https://ir.kyowakirin.com/en/library/earnings/earnings0/main/0118/teaserItems1/00/linkList/0/link/summary_2026_q2_en.pdf] (KYKOF [https://seekingalpha.com/symbol/KYKOF])...
European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union
Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal developmen...
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
Companies like Biogen and Royalty Pharma (Litifilimab), Biogen and UCB(Dapirolizumab pegol), Idorsia Pharmaceuticals and Viatris (Cenerimod), Novartis (Ianalumab, YTB3231), Kyowa Kirin (KK-4277), and ...
Get Kyowa Kirin Co. Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
